BLMH / Bleomycin Hydrolase Antibody (Antigen Affinity Purified)

BLMH / Bleomycin Hydrolase Antibody ( Antigen Affinity Purified ) Datasheet

BLMH / Bleomycin Hydrolase Antibody Product Information

• Immunogen: Recombinant Mouse BLMH / Bleomycin Hydrolase protein (Catalog#50668-M07E)
• Antibody Type: Rabbit Polyclonal Antibody ( Antibody Purification Platform )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, recombinant Mouse BLMH / Bleomycin Hydrolase (rM BLMH / Bleomycin Hydrolase; Catalog#50668-M07E; NP_848760.1; Asn 2-Glu 455). BLMH / Bleomycin Hydrolase specific IgG was purified by Mouse BLMH / Bleomycin Hydrolase affinity chromatography.

BLMH / Bleomycin Hydrolase Antibody Usage Guide

• Specificity: Mouse BLMH / Bleomycin Hydrolase
• Western blot: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Mouse BLMH in WB. Using a DAB detection system, the detection limit for Mouse BLMH is approximately 0.5 ng/lane under non-reducing conditions and reducing conditions.
• Direct ELISA: This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Mouse BLMH. The detection limit for Mouse BLMH is approximately 0.00245 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

BLMH / Bleomycin Hydrolase Antibody Background

Bleomycin hydrolase, also known as BLM hydrolase and BLMH, is cytoplasm protein which belongs to thepeptidase C1 family. BLM hydrolase / BLMH is a cytoplasmic cysteine peptidase that is highly conserved through evolution. The only known activity of the enzyme is metabolic inactivation of the glycopeptide bleomycin (BLM), an essential component of combination chemotherapy regimens for cancer. It catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity. BLM hydrolase / BLMH contains the signature active site residues of the cysteine protease papain superfamily. BLM hydrolase / BLMH inactivates bleomycin B2 (a cytotoxic glycometallopeptide) by hydrolysis of a carboxyamide bond of beta-aminoalanine, but also shows general aminopeptidase activity. The specificity varies somewhat with source, but amino acid arylamides of Met, Leu and Ala are preferred. BLM-induced death and has an important role in neonatal survival and in maintaining epidermal integrity. Mice lacking BLMH exhibited variably penetrant tail dermatitis that resembled rodent ringtail. The histopathology of the tail dermatitis was similar to skin lesions in humans with pellagra, necrolytic migratory erythema, and acrodermatitis enteropathica.

References

1. Montoya SE, et al., 1997, Cancer Res. 57 (19): 4191-5.
2. Koldamova, R P; et al.,1998, Mol. Pharmacol.54 (6): 954-61.
3. Ferrando AA, et al., 1998,J Biol Chem272 (52): 33298-304.
4. Schwartz,D.R. et al., 1999,Proc Natl Acad Sci USA. 96 (8):4680-5.
5. Lefterov, I M, et al.,2000, FASEB J.14 (12): 1837-47.